Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-TNF), which are increasingly used to treat patients with moderate-to-severe IBD older than 6 years who had an inadequate response with corticosteroids or immunomodulators [11,12]. Here, TNF is linked to inflammatory bowel disease.